No Data
No Data
No Data
Part 2 of stock movements the day before, including Zain Electronics, GMO-AP, and J-DEP Advance.
Company name <Code> on May 1 closing price ⇒ compared to the previous day: Marumae <6264> 2030 -703-5 Surprising lack of announcements for the bottom of fiscal year income. Kasumigaseki Capital <3498> 13310 -530 Tomorrow's earnings reports are expected to sell off. Attrae <6194> 777 -33 Significant increase in dividends last weekend. FP Partner <7388> 2765 -160 Rise due to buyback last weekend leads to sell-off. Asics <7936> 2373.5 -87.5 US distribution.
Active and newly listed stocks during the morning session.
*Nagano Keiki <7715> increased by 490 to 3440. Ichiiyoshi Securities has newly rated it as "A". *J. Front Retailing <3086> increased by 214 to 1891.5, upwardly revised its full-year financial estimates due to its 1Q earnings exceeding expectations. *Takashimaya <8233> increased by 214 to 2921.5, upwardly revised its business performance estimates due to strong inbound sales. *Yamashin Filter <6240> has also attracted attention as a corner of Trump-related stocks. *Kawasaki Kisen Kaisha <9107> increased by 13 to 2478.
Steady, with a pass in the PCE price index, buying on dips is dominant.
[Emerging markets individual stock strategy] Today's emerging markets are expected to show a steady development. In the US stock market on June 28, the Dow Jones average fell slightly by 45.20 dollars (-0.12%) to 39,118.86 dollars, and fell for the third day. Concerns about the acceleration of inflation subsided due to the slowness of the May PCE price index (core) and the fact that the June Michigan Consumer Confidence Index exceeded expectations, serving as a support for stock prices. On the other hand, sporting goods maker Nike, whose earnings were disappointing, weighed down the market.
Nifty Life, Perseus, and others.
<4262> Nifty Life revises its financial estimates, this year's revenue outlook is 4.764 billion yen, increased from 3.946 billion yen. <4593> Extends basic agreement period with Helios Snowbell Pharma. <4882> Perseus PPMX-T003: Polycythemia vera (PV) Phase I trial has been completed. <4888> Stella Pharma will issue large amount of subscription rights (with price adjustment clause) from the 13th, with 541,000 shares. <7066> Piazz IT Works School Business (BOOT CAMP)
Serendip Holdings: Confirmation letter
Serendip Holdings: Securities Report - 19th Fiscal Year (April 1, 2023 - March 31, 2024)
No Data